View Exam | PowerPak

1. What percentage of the heart failure population has anemia?

A. 20% B. 35% C. 50% D. 65%

2. What percentage of the heart failure population without anemia has iron deficiency?

A. 10% B. 20% C. 30% D. 40%

3. In observational studies, which of the following consequences were experienced by both heart failure (HF) patients with anemia and HF patients with iron deficiency?

A. Increased mortality and reduced quality of life (QOL) B. Reduced QOL and reduced renal function C. Reduced renal function and mortality D. There are no adverse consequences of anemia or iron deficiency that are shared

4. What does the literature suggest about the use of erythropoietin-stimulating agents in heart failure patients to increase hemoglobin concentrations above 13 g/dL?

A. It enhances quality of life but may have negative effects on embolic and thrombotic events B. It increases overall mortality C. It reduces the occurrence of embolic and thrombotic events and reduces quality of life D. It decreases overall mortality

5. Which of the following 2 iron products evaluated in a meta-analysis of clinical trials improved New York Heart Association functional class, 6-minute walk distances, and quality of life and reduced hospitalizations?

A. Iron sucrose, iron gluconate B. Iron gluconate, ferric carboxymaltose C. Ferric carboxymaltose, iron sucrose D. Ferrous sulfate, ferric carboxymaltose

6. When iron and erythropoietin-stimulating agents (ESAs) are used together in heart failure patients with iron deficiency but without severe anemia, what are the effects on hemoglobin (Hb) concentrations?

A. Iron and ESAs together achieve significantly better improvements in Hb concentrations than either agent alone B. Iron and ESAs together achieve Hb improvements that are similar to either agent alone C. Iron and ESAs together achieve Hb improvements that are worse than either agent alone D. Iron and ESAs have not been evaluated together in any studies

7. Which of the following iron supplementation regimens have NOT been shown to improve heart failure outcomes?

A. Ferric carboxymaltose 200 mg weekly for 5 weeks B. Iron sucrose 200 mg weekly for 5 weeks C. Ferric carboxymaltose 500 to 1000 mg every 6 weeks for 2 doses D. Iron sucrose 500 to 1000 mg every 6 weeks for 2 doses

8. Which of the following adverse events can rarely occur in patients within 30 minutes of administration of intravenous iron, necessitating at least 30 minutes of clinician monitoring after administration?

A. Hypotension, unconsciousness, and shock B. Hypertension, stroke, and death C. Bradycardia, angioedema, and deep venous thrombosis D. Tachycardia, pulmonary embolism, and diplopia

9. Which one of the following is NOT a commonly reported chronic adverse effect of intravenous iron?

A. Vomiting B. Dizziness C. Nystagmus D. Headache

10. Pharmacists play important roles in detecting iron deficiency and counseling about appropriate supplementation. Which of the following is NOT an example of an activity in which pharmacists should engage to enhance patient care?

A. Pharmacists in the community can discuss the impact of iron deficiency and anemia with their patients who have heart failure (HF), which improves patients' chances of being screened and treated B. Pharmacists in the hospital can design protocols to guide when iron supplementation should be given and how it should be administered C. Pharmacists in the hospital can perform drug use evaluations to ensure that the iron deficiency in HF protocol is being followed for quality assurance D. Pharmacists should be the primary clinicians diagnosing iron deficiency and injecting intravenous iron products